Emmett L, Subramaniam S, Crumbaker M, Nguyen A, et al. [(177)Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol 2024 Apr 12:S1470-2045(24)00135.
PMID: 38621400